BioSpace News Archive

Oxford BioTherapeutics Ltd. announces it has entered into a collaboration with Groupe d’Oncologie Radiothérapie Tête Et Cou to undertake a new Phase 1b trial investigating OBT’s lead asset, OBT076, in patients with Adenoid Cystic Carcinoma.

Asensus Surgical, Inc. announced that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright In-Person Bio-Connect Investor Conference.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 3:00 p.m. EDT.

Annovis Bio, Inc. today announced that patient recruitment for the Company’s Phase 2/3 study of buntanetap for the treatment of moderate Alzheimer’s disease (AD) remains consistent with its planned development program.

Revolo Biotherapeutics (“Revolo” or the “Company”) today announced positive topline data from its proof of concept Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of the company’s immune-resetting drug, ‘1104, in adults with active eosinophilic esophagitis (EoE).

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.

Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin’s senior management team to discuss the Company’s first quarter 2023 financial results on Wednesday, May 3rd, 2023 at 8:00 a.m. ET.

Virax Biolabs Group Limited announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.

A recently published study from Stanford University [see link] demonstrated the potential benefits of photobiomodulation (PBM) in a mouse model of neuroinflammation.